Of these, 27 lesions (56.3%) underwent HER2-targeted PET/CT imaging prior to the initiation of anti-tumor therapy, while the remaining 21 lesions (43.8%) were imaged during anti-tumor therapy. This evidence concerns the gene ERBB2 and neoplasm.